Atea Pharmaceuticals annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
Atea Pharmaceuticals R&D Spending Growth & History (AVIR)
Atea Pharmaceuticals's r&d spending was $148.0M for fiscal 2025.
View full Atea Pharmaceuticals company overviewAtea Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $148.0M | $3.9M | +2.72% |
| 2024 | 2024-12-31 | $144.1M | $29.9M | +26.14% |
| 2023 | 2023-12-31 | $114.2M | $32.3M | +39.43% |
| 2022 | 2022-12-31 | $81.9M | −$85.3M | −51.00% |
| 2021 | 2021-12-31 | $167.2M | $129.2M | +339.75% |
| 2020 | 2020-12-31 | $38.0M | $27.9M | +273.87% |
| 2019 | 2019-12-31 | $10.2M | $3.5M | +52.36% |
| 2018 | 2018-12-31 | $6.7M | — | — |
Atea Pharmaceuticals quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $28.1M | −$4.1M | −12.78% |
| Q1 2026 | 2026-03-31 | $41.1M | $11.6M | +39.04% |
| Q4 2025 | 2025-12-31 | $47.8M | $22.1M | +86.27% |
| Q3 2025 | 2025-09-30 | $38.3M | $12.2M | +46.59% |
| Q2 2025 | 2025-06-30 | $32.3M | −$2.4M | −6.98% |
| Q1 2025 | 2025-03-31 | $29.6M | −$28.0M | −48.62% |
| Q4 2024 | 2024-12-31 | $25.7M | −$9.4M | −26.75% |
| Q3 2024 | 2024-09-30 | $26.2M | −$2.0M | −7.18% |
| Q2 2024 | 2024-06-30 | $34.7M | $12.6M | +57.26% |
| Q1 2024 | 2024-03-31 | $57.6M | $28.6M | +98.85% |
| Q4 2023 | 2023-12-31 | $35.0M | $7.5M | +27.25% |
| Q3 2023 | 2023-09-30 | $28.2M | $23.3M | +474.54% |
| Q2 2023 | 2023-06-30 | $22.1M | $2.2M | +11.10% |
| Q1 2023 | 2023-03-31 | $29.0M | −$679,000 | −2.29% |
| Q4 2022 | 2022-12-31 | $27.5M | −$30.3M | −52.36% |
| Q3 2022 | 2022-09-30 | $4.9M | −$38.1M | −88.60% |
| Q2 2022 | 2022-06-30 | $19.9M | −$19.9M | −50.11% |
| Q1 2022 | 2022-03-31 | $29.6M | $3.1M | +11.52% |
| Q4 2021 | 2021-12-31 | $57.8M | $44.0M | +317.54% |
| Q3 2021 | 2021-09-30 | $43.0M | $29.4M | +216.29% |
| Q2 2021 | 2021-06-30 | $39.8M | $32.0M | +413.26% |
| Q1 2021 | 2021-03-31 | $26.6M | $23.8M | +841.90% |
| Q4 2020 | 2020-12-31 | $13.8M | — | — |
| Q3 2020 | 2020-09-30 | $13.6M | $11.2M | +464.12% |
| Q2 2020 | 2020-06-30 | $7.8M | — | — |
| Q1 2020 | 2020-03-31 | $2.8M | — | — |
| Q3 2019 | 2019-09-30 | $2.4M | — | — |
Atea Pharmaceuticals r&d spending trends
Over the last five fiscal years, Atea Pharmaceuticals's r&d spending increased from $38.0M to $148.0M, a change of $110.0M. The latest reported quarter, Q2 2026, shows $28.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Atea Pharmaceuticals source filings ↗